Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-07-06 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2022 annual equity distribution (dividend) plan approved at the shareholders' meeting. It details the dividend amount, tax treatment, record dates, and payment method. It does not contain full financial statements or comprehensive financial performance data, but focuses on dividend distribution specifics. This matches the definition of a Notice of Dividend Amount (DIV). The document length is short (1919 characters) and it is not merely announcing the publication of a report but providing detailed dividend distribution information.
2023-07-06 Chinese
关于认定核心员工的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the identification of core employees. It details the approval process by the board and shareholders, lists the names of the core employees, and references related meeting resolutions. There is no financial data, earnings information, or regulatory filings about financial performance. The content focuses on management and personnel decisions, specifically the recognition of key employees, which aligns with announcements about board or management information. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report or a certification, so it is not RNS or RPA.
2023-07-06 Chinese
2022年年度报告（更正公告）
Report Publication Announcement Classification · 95% confidence The document is titled as a "2022 Annual Report Correction Announcement" for Sichuan Zitonggong Pharmaceutical Co., Ltd. It references the original 2022 Annual Report disclosed on April 26, 2023, and details corrections to certain sections, specifically about major events and regulatory penalties. The document explicitly states that the corrections do not affect the company's 2022 financial status or operating results. The length of the document is 2724 characters, which is relatively short and primarily serves to announce corrections to a previously published annual report rather than presenting the full annual report itself. It also includes references to other announcements and reports on the exchange website. According to the "Menu vs Meal" rule, since this document is a correction announcement and not the full annual report, and given its short length, it should be classified as a Report Publication Announcement (RPA) rather than the Annual Report (10-K).
2023-07-06 Chinese
关于2023年股权激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to the company's 2023 equity incentive plan. It details the investigation scope, procedures, findings, and conclusions about insider trading compliance. The content focuses on regulatory compliance and insider trading checks rather than financial results, management changes, or shareholder voting. It is not a financial report, earnings release, or management discussion. It is a regulatory disclosure about insider trading compliance related to an equity incentive plan. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-06 Chinese
2022年年度报告（更正后）
Annual Report Classification · 100% confidence The document is titled '年度报告 2022' which translates to 'Annual Report 2022'. It contains detailed sections typical of an annual report such as company overview, accounting data and financial indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal control, and financial accounting reports. The document includes audited financial data, management discussion, risk disclosures, and detailed financial statements. The presence of an audit opinion from an accounting firm further supports this classification. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document is best classified as an Annual Report (10-K). FY 2022
2023-07-06 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2023年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and voting results of the company's 2023 third extraordinary general meeting of shareholders. It details the legality and validity of the meeting's convening, attendance, voting procedures, and results. It does not contain financial statements or financial performance data but focuses on the validation of the shareholder meeting process and voting outcomes. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is 4345 characters, which is sufficient to contain detailed voting results and legal opinions, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2023-07-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.